About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a publicly listed company based in Pasadena (United States) founded in 1989, and was acquired by Regal Rexnord in November 2021. Therapeutics for intractable diseases are developed via gene silencing. It operates on a HealthTech model. Arrowhead Pharmaceuticals has raised $110.98 million across 13 funding rounds from investors including Silence Therapeutics, Orbimed and Regal Rexnord. The company has 609 employees. Its chief executive, as recorded, is Christopher Anzalone. Its website arrowheadpharma.com draws about 62 thousand monthly visits. Arrowhead Pharmaceuticals offers products and services including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE. Its focus areas include Biotechnology and RNAi Therapeutics. Its legal entity is Arrowhead Pharmaceuticals, Inc. Its competitors include AbbVie, Lilly and Biogen; 1 of its 3 listed competitors has raised funding.
Company details
Arrowhead Pharmaceuticals is engaged in the development of innovative therapeutics using RNA interference (RNAi) technology. The company targets genes causing diseases in areas such as cardiometabolic disorders, severe hypertriglyceridemia, dyslipidemia, cardiovascular disease, and pulmonary inflammatory diseases. Solutions are built on the proprietary TRiM platform, which leverages natural pathways to silence disease-causing genes. Clinical trials are conducted across multiple phases to address significant unmet medical needs. The portfolio includes drug candidates like Plozasiran, Zodasiran, and ARO-RAGE, aimed at diverse therapeutic areas. Operations span various global locations to support research and development efforts.
- Headquarters Pasadena, United States
- Employees 609
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website arrowheadpharma.com
- Social LinkedIn X Facebook Instagram
- Acquired by Regal Rexnord (Nov 2021)
- Legal Name Arrowhead Pharmaceuticals, Inc.
- Annual Revenue$829.45 M (USD)23258.15as on Sep 30, 2025
- Net Profit-$1.63 M (USD)99.73as on Sep 30, 2025
- EBITDA$122.27 M (USD)as on Sep 30, 2025
- Total Equity Funding$110.98M (USD)
in 13 rounds
- Latest Funding Round$7.2M (USD), Post-IPO
Dec 2017
- InvestorsSilence Therapeutics
& 6 more
- Employee Count609
- Acquired byRegal Rexnord
(Nov 2021)
Products & Services of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals offers a comprehensive portfolio of products and services, including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE.
Developed to reduce triglycerides in severe hypertriglyceridemia patients.
Designed to lower LDL in dyslipidemia treatment cases.
Created for treating inflammatory pulmonary diseases effectively.
Funding Insights of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has successfully raised a total of $110.98M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.2 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110.98M
- Total Rounds 13
- Last Round Post-IPO — $7.2M
- First Round $2.76M
(Aug 2009)
- Investors Count 6
Latest 10 of 13 funding rounds of Arrowhead Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $7.2M | Post-IPO | – | – | |
| Jan 2017 | $9.7M | Post-IPO | – | – | |
| Sep 2016 | $56.5M | Post-IPO | – | – | |
| Aug 2016 | $45M | Private Equity Round | – | – | |
| Aug 2016 | $45M | Post-IPO | – | – | |
| Oct 2013 | $64M | Post-IPO | – | – | – |
| Oct 2013 | $60M | Private Equity Round | – | – | – |
| May 2013 | $36M | Post-IPO | – | – | – |
| Oct 2011 | $5.5M | Post-IPO | – | – | – |
| Jan 2010 | $3.22M | Private Equity Round | – | – | – |
7 investors in total: 7 institutional.
Investors in Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Silence Therapeutics, Orbimed and Regal Rexnord.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | silence-therapeutics.com | London, United Kingdom | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Manufacturer of electric motors and power transmission components | 1955 | regalrexnord.com | Milwaukee, United States |
Investor details for Arrowhead Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arrowhead Pharmaceuticals
144 people are tracked at Arrowhead Pharmaceuticals (60 in leadership, 7 in board & advisors, 77 in team); the tracked headcount is 609.
| Name | Role | Group |
|---|---|---|
Christopher Anzalone | CEO & President | Leadership |
James Hamilton | Chief Discovery & Translational Medicine | Leadership |
Lashana P. | Associate Director, Payroll & Benefits | Leadership |
Grigoriy Shekhtman | Senior Medical Director Clinical Development | Leadership |
Holly Hamilton | Director, Bioassays | Leadership |
Jing Chen | Director Discovery DMPK | Leadership |
Anjli Warner | Vice President, Head Of Business Development & New Product Planning | Leadership |
Zhi-Ming Ding | VP, Biology | Leadership |
Cathy Kealy | Associate Director, Financial Services | Leadership |
Eleonora Goldberg | Vice President Medical Affairs | Leadership |
Michelle Bernards | Director, Quality Management System | Leadership |
Neelone Cestkowski | Director, Supply Chain Quality | Leadership |
Patrick C. O’Brien | COO & General Counsel | Leadership |
Janna Jagoe | Executive Director, Global Head Of Marketing And Sales | Leadership |
Kostadin Basamakov | Head Of Business Analytics And Market Insights | Leadership |
Shicheng Guo | Senior Director, Translational Genetics And Data Science | Leadership |
Ken Myszkowski | CFO | Leadership |
Phedellee Reyes | Associate Director, Clinical Operations | Leadership |
Suping Zheng | Director | Leadership |
Ping Jin | Associate Director | Leadership |
124 more people are available in the full profile.
Complete people profiles for Arrowhead Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ARWR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 1993
- Listed onNASDAQ: ARWR
- Listed entityArrowhead Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS04280A1007
- Share price$58.13 (-4.28% on the day) · 2026-10-13
- Market capitalisation$8.21B
- EPS (diluted, trailing year)$-2.24
- Volume (last session)2,260,925
Financials of Arrowhead Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $829.5M | -$1.6M | $122.3M |
| 2024 | $3.5M | -$599.5M | -$582.5M |
| 2023 | $240.7M | -$205.3M | -$192.5M |
| 2022 | $243.2M | -$176.1M | -$168.1M |
| 2021 | $138.3M | -$140.8M | -$140.8M |
Detailed financial statements for Arrowhead Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arrowhead Pharmaceuticals
5 dated milestones of Arrowhead Pharmaceuticals across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Arrowhead Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.8M.
- Funding Latest funding round, Post-IPO, of $7.2M.
- Exit Acquired by Regal Rexnord.
Competitors of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has 3 listed competitors in our database, 1 of them funded. They include AbbVie, Lilly and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | ||
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Arrowhead Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arrowhead Pharmaceuticals
The website of Arrowhead Pharmaceuticals (arrowheadpharma.com) receives about 61.8K visits a month and ranks #782,346 among all websites worldwide, #925 in Biotechnology and Pharmaceuticals.
- Monthly visits61.8K
▲ 62.3% vs previous month
- Unique visitors17K
per month
- Global rank#782,346
among all websites
- Category rank#925
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.2
- Average visit58 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Arrowhead Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nimbustx.com | 100% | 15.2K | #2,193,568 | View details | |
jobs.takeda.com | jobs.takeda.com | 95% | #185,912 | – | |
| amgen.com | 95% | 495.4K | #116,434 | View details | |
bioworld.com | bioworld.com | 95% | #311,180 | – | |
| clinicaltrialsarena.com | 95% | #257,942 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Arrowhead Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Arrowhead Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arrowhead Pharmaceuticals
Complete news archive for Arrowhead Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals was founded in 1989 and raised its 1st funding round 20 years after it was founded.
Arrowhead Pharmaceuticals is headquartered in Pasadena, United States. It is registered at Pasadena, California, United States.
Christopher Anzalone is the CEO of Arrowhead Pharmaceuticals, as recorded in our data.
Arrowhead Pharmaceuticals is a funded company, having raised a total of $110.98M across 13 funding rounds to date. The company's 1st funding round was a Private Equity Round of $3.22M, raised on Aug 2009.
Arrowhead Pharmaceuticals has 609 employees.
Annual revenue of Arrowhead Pharmaceuticals is $829.45M as on Sep 30, 2025.
Arrowhead Pharmaceuticals is engaged in the development of innovative therapeutics using RNA interference (RNAi) technology. The company targets genes causing diseases in areas such as cardiometabolic disorders, severe hypertriglyceridemia, dyslipidemia, cardiovascular disease, and pulmonary inflammatory diseases. Solutions are built on the proprietary TRiM platform, which leverages natural pathways to silence disease-causing genes. Clinical trials are conducted across multiple phases to address significant unmet medical needs. The portfolio includes drug candidates like Plozasiran, Zodasiran, and ARO-RAGE, aimed at diverse therapeutic areas. Operations span various global locations to support research and development efforts.
Arrowhead Pharmaceuticals offers Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE.
Yes, Arrowhead Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ARWR.
Arrowhead Pharmaceuticals has 7 investors. Key investors include Silence Therapeutics, Orbimed, Regal Rexnord, RTW Investments, and RA Capital.
Arrowhead Pharmaceuticals operates through Arrowhead Pharmaceuticals, Inc..